The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon

Gut

Volumn 65, Issue 3, 2016, Pages 456-464

  Grimm, Wesley A ^a   Messer, Jeannette S ^a   Murphy, Stephen F ^a   Nero, Thomas ^a   Lodolce, James P ^a   Weber, Christopher R ^a   Logsdon, Mark F ^a   Bartulis, Sarah ^a   Sylvester, Brooke E ^a   Springer, Amanda ^a   Dougherty, Urszula ^a   Niewold, Timothy B ^a   Kupfer, Sonia S ^a   Ellis, Nathan ^a   Huo, Dezheng ^a   Bissonnette, Marc ^a   Boone, David L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; ATG16L1 PROTEIN, HUMAN; AUTOPHAGY RELATED PROTEIN; CARRIER PROTEIN; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; AGED; AMINO ACID SUBSTITUTION; ARTICLE; ATG16L1 GENE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COLON CANCER CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FOLLOW UP; GENE; GENE FREQUENCY; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MIDDLE AGED; MITOCHONDRIAL ANTIVIRAL SIGNALLING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; COLORECTAL TUMOR; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AUTOPHAGY-RELATED PROTEINS; BIOMARKERS, TUMOR; CARRIER PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 84960404438     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308735     Document Type: Article

References (50)

1. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol 2009;10:461-70.
2. Messer JS, Murphy SF, Logsdon MF, et al. The Crohn's disease-associated ATG16L1 variant and Salmonella invasion. BMJ Open 2013;3:pii: e002790.
3. Subramani S, Malhotra V. Non-autophagic roles of autophagy-related proteins. EMBO Rep 2013;14:143-51.
4. Jounai N, Takeshita F, Kobiyama K, et al. The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci USA 2007;104:14050-5.
5. Hwang S, Maloney NS, Bruinsma MW, et al. Nondegradative role of Atg5-Atg12/Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 2012;11:397-409.
6. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
7. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-11.
8. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS ONE 2008;3:e3391.
9. Fujita N, Saitoh T, Kageyama S, et al. Differential involvement of Atg16L1 in Crohn disease and canonical autophagy: analysis of the organization of the Atg16L1 complex in fibroblasts. J Biol Chem 2009;284:32602-9.
10. Huijbers A, Plantinga TS, Joosten LA, et al. The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. Endocr Relat Cancer 2012;19:L15-18.
11. Fuertes MB, Woo SR, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2012;34:67-73.
12. Katayama T, Nakanishi K, Nishihara H, et al. Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells. Int J Oncol 2007;31:613-20.
13. Kubler K, Gehrke N, Riemann S, et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010;70:5293-304.
14. Cao G, Su J, Lu W, et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001;8:497-505.
15. Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131:387-95.
16. Bidwell BN, Slaney CY, Withana NP, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012;18:1224-31.
17. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011;71:2488-96.
18. Kubler K, tho Pesch C, Gehrke N, et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly (I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol 2011;41:3028-39.
19. Ogasawara K, Hida S, Azimi N, et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-3.
20. Swann JB, Hayakawa Y, Zerafa N, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007;178:7540-9.
21. Hornung V, Ellegast J, Kim S, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7.
22. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005;6:981-8.
23. Tang ED, Wang CY. MAVS self-association mediates antiviral innate immune signaling. J Virol 2009;83:3420-8.
24. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
25. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010;141:1135-45.
26. Marchiando AM, Ramanan D, Ding Y, et al. A deficiency in the autophagy gene Atg16L1 enhances resistance to enteric bacterial infection. Cell Host Microbe 2013;14:216-24.
27. Lei Y, Wen H, Yu Y, et al. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012;36:933-46.
28. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010;6:40-9.
29. Fu XY, Kessler DS, Veals SA Jr, et al. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci USA 1990;87:8555-9.
30. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-63.
31. Clark PI, Slevin ML, Reznek RH, et al. Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. Int J Colorectal Dis 1987;2:26-9.
32. Gennatas C, Mouratidou D, Androulakis G, et al. Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma. Tumori 2002;88:32-6.
33. Schippinger W, Jagoditsch M, Sorre C, et al. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer 2005;92:1655-62.
34. Tarhini AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol 2012;189:3789-93.
35. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986;68:493-7.
36. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014;232:199-209.
37. Hammill AM, Conner J, Cripe TP. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 2010;55:1253-63.
38. Lun X, Ruan Y, Jayanthan A, et al. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol 2013;7:944-54.
39. Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-9.
40. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
41. Sheridan C. Amgen announces oncolytic virus shrinks tumors. Nat Biotechnol 2013;31:471-2.
42. Matsushima-Miyagi T, Hatano K, Nomura M, et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012;18:6271-83.
43. Zhang Q, Xu X, Yuan Y, et al. IPS-1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virus. Int J Cancer 2014;134:224-34.
44. Moerdyk-Schauwecker M, Shah NR, Murphy AM, et al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 2013;436:221-34.
45. Murphy AM, Besmer DM, Moerdyk-Schauwecker M, et al. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 2013;86:3073-87.
46. Joubert PE, Werneke SW, de la Calle C, et al. Chikungunya virus-induced autophagy delays caspase-dependent cell death. J Exp Med 2012;209:1029-47.
47. Koshiba T, Yasukawa K, Yanagi Y, et al. Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling. Sci Signal 2011;4:77ra7.
48. Castanier C, Garcin D, Vazquez A, et al. Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep 2010;11:133-8.
49. Tal MC, Sasai M, Lee HK, et al. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci USA 2009;106:2770-5.
50. Lee HK, Lund JM, Ramanathan B, et al. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 2007;315:1398-401.